Titlebook: Rare Disease Drug Development; Clinical, Scientific Raymond A. Huml Book 2021 The Editor(s) (if applicable) and The Author(s), under exclus

Arthur

書目名稱Rare Disease Drug Development影響因子(影響力)




書目名稱Rare Disease Drug Development影響因子(影響力)學(xué)科排名




書目名稱Rare Disease Drug Development網(wǎng)絡(luò)公開度




書目名稱Rare Disease Drug Development網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Rare Disease Drug Development被引頻次




書目名稱Rare Disease Drug Development被引頻次學(xué)科排名




書目名稱Rare Disease Drug Development年度引用




書目名稱Rare Disease Drug Development年度引用學(xué)科排名




書目名稱Rare Disease Drug Development讀者反饋




書目名稱Rare Disease Drug Development讀者反饋學(xué)科排名

尖

http://image.papertrans.cn/r/image/821231.jpg

ULCER

https://doi.org/10.1007/978-3-030-78605-2Rare disease; drug development; caregivers; orphan drug; disease-modifying treatments

CESS

抱狗不敢前

SENT

Introduction to Rare Diseases and Market Overview, and attempt to identify approaches to target those mechanisms to modify or perhaps cure the disease. Only a small number of rare diseases had approved therapies..Since then, there has been a marked increase in rare disease research funding and development effort, thanks to regulatory changes, multi

引導(dǎo)

Select Patient Narratives,nto the rare disease drug development and approval processes. Rare disease patients are the most appropriate individuals to consult in order to identify and rank the importance of the conditions that they face..This chapter will provide multiple views from persons/patients afflicted with different r

教義

A Mental Health Perspective,hapter will define terms related to mental health, provide an overview of the current state of mental health in the rare disease population, discuss the gaps and unmet needs that have been identified, and offer considerations for strategies and measures to address the gaps in providing mental health

增減字母法

陳舊